Clinical Trials Browser

Phase 1/2 × tocilizumab × 30 days × Clear all

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT05583617 2026-03-06

PLYCOM

Phase 1/2 Recruiting

Multiple Myeloma

NCT03075696 2026-03-05

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Phase 1/2 Recruiting

940 enrolled 1 FDA

Lymphoma, Non-Hodgkin

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT04524871 2026-02-27

MORPHEUS-LIVER

Phase 1/2 Recruiting

Advanced Liver Cancers